CD271 has been applied to isolate mesenchymal stem cells (MSCs) from bone marrow and other tissues. Umbilical cord blood is a unique resource of stem cells and endothelial progenitor cells. Isolation of MSCs from umbilical cord blood, however, has been inefficient and inconsistent. This study was designed to examine the potential application of CD271 as a marker for the isolation of MSCs from umbilical cord blood. CD271+ cells were isolated from umbilical cord blood and bone marrow using CD271 antibody-conjugated microbeads, and characterized in osteogenic, chondrogenic and adipogenic differentiation. CD271+ cells from umbilical cord blood were slow to proliferate compared with those isolated from bone marrow. While CD271+ cells from bone marrow differentiated into osteogenic, chondrogenic and adipogenic lineages, there were no sound indications of differentiation by CD271+ cells from umbilical cord blood under the same differentiation conditions applied to the CD271+ cells from bone marrow. The study also found that bone marrow CD271+ cells remarkably upregulated the expression of chondrogenic genes under chondrogenic differentiation induction. When implanted into bone defects in mice, CD271+ cells from bone marrow regenerated significant bone, but the counterparts in umbilical cord blood formed little bone in the bone defects. In conclusion, CD271 is an efficient marker for MSC isolation from bone marrow but has failed to isolate MSCs from umbilical cord blood. CD271+ cells in bone marrow are particularly chondrogenic. The property of CD271+ cells is unique but varies from different tissues.

1.
Aoyagi K., Y. Yamazaki, A. Matsuo, Y. Shimakura, A. Takeda, E. Uchinuma (2010) Significance of CD271 in bone marrow mesenchymal stem cells - changes by cryopreservation. J Craniofac Surg 21: 666-678.
2.
Arufe M.C., A. De la Fuente, I. Fuentes, F.J. de Toro, F.J. Blanco (2010) Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes. J Cell Biochem 111: 834-845.
3.
Aslan H., Y. Zilberman, L. Kandel, M. Liebergall, R.J. Oskouian, D. Gazit, Z. Gazit (2006) Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105+ cells. Stem Cells 24: 1728-1737.
4.
Barry F., R. Boynton, M. Murphy, S. Haynesworth, J. Zaia (2001) The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun 289: 519-524.
5.
Barry F.P., J.M. Murphy (2004) Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 36: 568-584.
6.
Bieback K., S. Kern, H. Klüter, H. Eichler (2004) Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22: 625-634.
7.
Boeuf S, W. Richter (2010) Chondrogenesis of mesenchymal stem cells: role of tissue source and inducing factors. Stem Cell Res Ther 1: 31.
8.
Boiret N., C. Rapatel, R. Veyrat-Masson, L. Guillouard, J.J. Guérin, P. Pigeon, S. Descamps, S. Boisgard, M.G. Berger (2005) Characterization of nonexpanded mesenchymal progenitor cells from normal adult human bone marrow. Exp Hematol 33: 219-225.
9.
Bühring H.J., V.L. Battula, S. Treml, B. Schewe, L. Kanz, W. Vogel (2007) Novel markers for the prospective isolation of human MSC. Ann NY Acad Sci 1106: 262-271.
10.
Deschaseaux F., F. Gindraux, R. Saadi, L. Obert, D. Chalmers, P. Herve (2003) Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45med, low phenotype. Br J Haematol 122: 506-517.
11.
Flores-Torales E., A. Orozco-Barocio, O.R. Gonzalez-Ramella, A. Carrasco-Yalan, K. Gazarian, S. Cuneo-Pareto (2010) The CD271 expression could be alone for establisher phenotypic marker in bone marrow derived mesenchymal stem cells. Folia Histochem Cytobiol 48: 682-686.
12.
Flynn A., F. Barry, T. O'Brien (2007) UC blood-derived mesenchymal stromal cells: an overview. Cytotherapy 9: 717-726.
13.
Goldstein G., A. Toren, A. Nagler (2007) Transplantation and other uses of human umbilical cord blood and stem cells. Curr Pharm Des 13: 1363-1373.
14.
Hermida-Gómez T., I. Fuentes-Boquete, M.J. Gimeno-Longas, E. Muiños-López, S. Díaz-Prado, F.J. de Toro, F.J. Blanco (2011) Bone marrow cells immunomagnetically selected for CD271+ antigen promote in vitro the repair of articular cartilage defects. Tissue Eng Part A 17: 1169-1179.
15.
Ho A.D., W. Wagner, W. Franke (2008) Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 10: 320-330.
16.
Jones E.A., A. English, S.E. Kinsey, L. Straszynski, P. Emery, F. Ponchel, D. McGonagle (2006) Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom 70: 391-399.
17.
Jones E.A., S.E. Kinsey, A. English, R.A. Jones, L. Straszynski, D.M. Meredith, A.F. Markham, A. Jack, P. Emery, D. McGonagle (2002) Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 46: 3349-3360.
18.
Madlambayan G., I. Rogers (2006) Umbilical cord-derived stem cells for tissue therapy: current and future uses. Regen Med 1: 777-787.
19.
Majumdar M.K., V. Banks, D.P. Peluso, E.A. Morris (2000) Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J Cell Physiol 185: 98-106.
20.
Mareschi K., E. Biasin, W. Piacibello, M. Aglietta, E. Madon, F. Fagioli (2001) Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 86: 1099-1100.
21.
Martins A.A., A. Paiva, J.M. Morgado, A. Gomes, M.L. Pais (2009) Quantification and immunophenotypic characterization of bone marrow and umbilical cord blood mesenchymal stem cells by multicolor flow cytometry. Transplant Proc 41: 943-946.
22.
Mikami Y., Y. Ishii, N. Watanabe, T. Shirakawa, S. Suzuki, S. Irie, K. Isokawa, M.J. Honda (2011) CD271/p75(NTR) inhibits the differentiation of mesenchymal stem cells into osteogenic, adipogenic, chondrogenic, and myogenic lineages. Stem Cells Dev 20: 901-913.
23.
Olsen B.R. (1997) Collagen IX. Int J Biochem Cell Biol 29: 555-558.
24.
Paprocka M., A. Krawczenko, D. Dus, A. Kantor, A. Carreau, C. Grillon, C. Kieda (2011) CD133 positive progenitor endothelial cell lines from human cord blood. Cytometry A 79: 594-602.
25.
Perdikogianni C., H. H. Dimitriou, E. Stiakaki, G. Martimianaki, M. Kalmanti (2008) Could cord blood be a source of mesenchymal stromal cells for clinical use? Cytotherapy 10: 452-459.
26.
Pittenger M.F., A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, D.R. Marshak (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
27.
Quirici N., D. Soligo, P. Bossolasco, F. Servida, C. Lumini, G.L. Delilier (2002) Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 30: 783-791.
28.
Rebelatto C.K., A.M. Aguiar, M.P. Moretão, A.C. Senegaglia, P. Hansen, F. Barchiki, J. Oliveira, J. Martins, C. Kuligovski, F. Mansur, A. Christofis, V.F. Amaral, P.S. Brofman, S. Goldenberg, L.S. Nakao, A. Correa (2008) Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood) 233: 901-913.
29.
Rozemuller H., H.J. Prins, B. Naaijkens, J. Staal, H.J. Bühring, A.C. Martens (2010) Prospective isolation of mesenchymal stem cells from multiple mammalian species using cross-reacting anti-human monoclonal antibodies. Stem Cells Dev 19: 1911-1921.
30.
Sibov T.T., P. Severino, L.C. Marti, L.F. Pavon, D.M. Oliveira, P.R. Tobo, A.H. Campos, A.T. Paes, E. Amaro Jr, L.F. Gamarra, C.A. Moreira-Filho (2012) Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation. Cytotechnology 64: 511-521.
31.
Soncini M., E. Vertua, L. Gibelli, F. Zorzi, M. Denegri, A. Albertini, G.S. Wengler, O. Parolini (2007) Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 1: 296-305.
32.
Wexler S.A., C. Donaldson, P. Denning-Kendall, C. Rice, B. Bradley, J.M. Hows (2003) Adult bone marrow is a rich source of human mesenchymal ‘stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 121: 368-374.
33.
Zaucke F., R. Dinser, P. Maurer, M. Paulsson (2001) Cartilage oligomeric matrix protein (COMP) and collagen IX are sensitive markers for the differentiation state of articular primary chondrocytes. Biochem J 358: 17-24.
34.
Zeddou M., A. Briquet, B. Relic, C. Josse, M.G. Malaise, A. Gothot, C. Lechanteur, Y. Beguin (2010) The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biol Int 34: 693-701.
35.
Zhang X., M. Hirai, S. Cantero, R. Ciubotariu, L. Dobrila, A. Hirsh, K. Igura, H. Satoh, I. Yokomi, T. Nishimura, S. Yamaguchi, K. Yoshimura, P. Rubinstein, T.A. Takahashi (2011) Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. J Cell Biochem 112: 1206-1218.
36.
Zhang Z., J.M. McCaffery, R.G. Spencer, C.A. Francomano (2004) Hyaline cartilage engineered by chondrocytes in pellet culture: histological, immunohistochemical and ultrastructural analysis in comparison with cartilage explants. J Anat 205: 229-237.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.